Unicycive Therapeutics
UNCY
30 hedge funds and large institutions have $49M invested in Unicycive Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 6 closing their positions.
157% more capital invested
Capital invested by funds: $19.1M → $49M (+$29.9M)
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
7% more funds holding
Funds holding: 28 → 30 (+2)
0.99% more ownership
Funds ownership: 4.96% → 5.94% (+0.99%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.19M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$3.04M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.34M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$798K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$838K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$277K |
| 3 |
LPL Financial
San Diego,
California
|
-$190K |
| 4 |
BFG
Bleakley Financial Group
Fairfield,
New Jersey
|
-$32.6K |
| 5 |
VF
Virtu Financial
New York
|
-$30K |
UNCY Hedge Fund Activity: Q4 2024 in Review
30 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q4 2024, worth a combined $49M — up 157% from $19.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new UNCY positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $4.19M. The largest seller was Silverarc Capital Management, cutting an estimated $838K.
- 30 institutional investors held Unicycive Therapeutics (UNCY) as of Q4 2024, up from 28 in Q3 2024.
- Funds reported $49M of Unicycive Therapeutics stock for Q4 2024, up 157% quarter-over-quarter.
- 8 funds opened new Unicycive Therapeutics positions in Q4 2024 and 6 closed out, a net change of +2 holders.
- The largest Unicycive Therapeutics buyer in Q4 2024 was Nantahala Capital Management, an estimated $4.19M added.
- The largest Unicycive Therapeutics seller in Q4 2024 was Silverarc Capital Management, an estimated $838K sold.
Based on aggregated 13F filings for Q4 2024.